Weekly symptom reporting in lung cancer, and longer survival

Design

Post hoc analysis of a stepped-wedge cluster-randomised trial

Population

446 patients with stage I–IV lung cancer, 14 Dutch centres

Primary outcome

Overall survival (post hoc)

Effect

Median 26 vs 21 months; adjusted HR 0.80 (95% CI 0.63–1.00)

SYMPRO-Lung was a stepped-wedge cluster-randomised trial in 14 Dutch hospitals. Patients with stage I–IV lung cancer starting a new treatment either received usual care or completed weekly online symptom questionnaires for a year, with alerts to the care team. Its primary outcome, quality of life, was reported earlier. This post hoc analysis, published in September, linked 446 of 515 patients to the national cancer registry.

At a median follow-up of 50 months, median overall survival was 26 months with symptom monitoring against 21 months with usual care (adjusted HR 0.80, 95% CI 0.63–1.00). Progression-free survival did not differ significantly.

The finding is consistent with earlier trials in advanced cancer, and it extends the idea to all stages in routine care. The likely mechanism is earlier recognition of complications and treatment toxicity. It does not need expensive technology: a structured weekly symptom check with a clear route to act on it is the core.

• Consider structured weekly symptom reporting for patients starting lung cancer treatment.
• Make sure every alert has a named clinician or nurse who acts on it.
• Use simple tools — phone, messaging or paper — where online systems are not available.
• Focus on symptoms that signal toxicity or complications, such as breathlessness, fever and pain.

Why it matters

A low-cost process change was associated with survival gains of the order seen with some new drugs.

Don't overread it

This was a post hoc survival analysis with an upper confidence bound of 1.00, so the benefit is uncertain in size.

The statistics, in plain English

An HR of 0.80 with an interval from 0.63 to 1.00 is right at the edge of statistical significance. A five-month median difference is meaningful, but this was not the trial's primary outcome.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.